Form 4: Beta Bionics Chief Commercial Officer Awarded Stock Options
SEC Form 4
Mark Hopman, Chief Commercial Officer of Beta Bionics, was granted multiple tranches of employee stock options on January 31, 2025.
Summary
- Mark Hopman, the Chief Commercial Officer of Beta Bionics, was granted several employee stock options on January 31, 2025.
- These options are for the purchase of common stock at various exercise prices.
- The options vest over different periods, generally monthly over 48 months, with some vesting starting earlier.
- The exercise prices for the options range from $5.10 to $17.00 per share.
- A total of 225,435 options were granted across the five tranches.
Sentiment
Score: 7
Explanation: The document reflects a standard practice of executive compensation through stock options, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
- The options provide an incentive for the executive to increase the company's value.
Risks
- The value of the options is dependent on the future performance of the company's stock price.
- If the stock price does not increase, the options may not be valuable to the executive.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for compensating executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedules and exercise prices are typical for such grants, designed to incentivize long-term performance.
- Companies like Insulet and Dexcom also use stock options as part of their executive compensation packages.
Stakeholder Impact
- The stock option grants may positively impact shareholder value if the executive's performance leads to an increase in the company's stock price.
- The grants incentivize the executive to work towards the long-term success of the company, which benefits all stakeholders.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of the stock option grants. |
| 02/03/2025 | Date the form was signed. |
| 03/20/2023 | Start date for vesting of the first tranche of options. |
| 09/14/2023 | Start date for vesting of the second tranche of options. |
| 01/01/2024 | Start date for vesting of the third tranche of options. |
| 09/30/2024 | Start date for vesting of the fourth tranche of options. |
| 01/29/2025 | Start date for vesting of the fifth tranche of options. |
| 07/26/2033 | Expiration date of the first tranche of options. |
| 09/13/2033 | Expiration date of the second tranche of options. |
| 12/31/2033 | Expiration date of the third tranche of options. |
| 09/29/2034 | Expiration date of the fourth tranche of options. |
| 01/28/2035 | Expiration date of the fifth tranche of options. |
Keywords
stock options, employee stock options, executive compensation, Beta Bionics, BBNX, Mark Hopman, vesting, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.